Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction Between GHB and Cobicistat
NCT04322214Phase 1Completed
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cobicistat in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoints: Concentration in plasma of GHB at Day 17 and Proportion of participants reporting adverse events at Day 28. Started Jan 2020; status: completed.
02
Drugs
cobicistat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04322214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322214.